All News

The medical team had reached some conclusions.

A wide-angle view of life with cancer.

A cancer survivor discusses a problem, even with good intentions, of the public's lack of cancer education.

Cancer is a solitary event, and in that isolation lies empowerment, one survivor has found.

Caregivers may grapple with practical and emotional challenges as they help loved ones manage cancer-related pain.

While the medical community delves into the mysteries of cancer and its undoing, we cancer survivors need immediate and long-term health practices that might tip the scale in our favor of survival.

Adding the immunotherapeutic vaccine Rintega (rindopepimut) to Avastin (bevacizumab) may help boost survival in patients with a genetic subtype of glioblastoma associated with poor outcomes.

Sharing your pain is scary, but leaning in to therapy was the best thing I did to heal emotionally from cancer.

Where our intrepid transplant recipient discovers that being a vampire isn't all it's cracked up to be.

Weary from chronic fatigue, chemo side effects and stress, I began thinking of ways to move beyond traditional treatment and cope with the increasing levels of anxiety. Something had to change cause I was sick and tired of being sick and tired.

By allowing oncologists to better understand treatment patterns and options, a new big-data system aims to ensure that patients will benefit from the most informed medical decisions as they fight cancer.

Get active in cancer advocacy, fight for increased medical research funding, and we won't need cancer awareness ribbons.

Clear the cancer clutter: Advice from a breast cancer and melanoma survivor.

Being diagnosed with cancer changes everything about your life. Yes, there are those few who have a simple diagnosis, breeze through treatment and then actually get back to some form of "normal" — the life they lived before they heard the words, It's cancer.

Backpacking through Nepal, two magicians discover a life-changing secret.

Walking can help the chemo and post-surgical cancer patient in many ways.

Treatment with a new PARP inhibitor called rucaparib demonstrated robust clinical activity and a tolerable safety profile for women with biomarker-defined relapsed ovarian cancer.

A melanoma survivor shares her experience and ideas.

When people think of cancer too often fear gets in the way of allowing us to look past the cancer itself and to the people who have been diagnosed with the disease.

When you're told you're sick, you're also told that you're an insta-inspiration, and your will to fight is somehow supposed to grow as your suffering does. Being sick doesn't always make sense.

Cancer patients need more than any necessary conventional cancer treatments. Solutions come from integrative cancer care for the whole person. Learn about why, how to achieve optimal health and healing, and some top-notch resources.

Some days it's just a day to cry. But that's OK.

Has cancer changed your perspective on life? What do you value most? What do you most desire?

This is how I became hospital property.

The community of patients and caregivers supports us through our cancer journey.

Better treatment and follow-up are being credited with a reduction in the likelihood that survivors of childhood cancers will later die of illnesses caused by their therapy, such as new malignancies or cardiac or lung disease.

When cancers that originate elsewhere cause small metastases in the brain, initial treatment should not routinely be followed by whole brain radiation therapy, because that strategy dramatically increases the chances of cognitive decline without improving survival outcomes.

Adding the chemotherapy docetaxel to standard combination hormonal and radiation therapy boosted survival rates in patients with high-risk localized prostate cancer, according to a study.

The American Society of Clinical Oncology is testing what will happen if patients are treated according to the genomics of their tumors, rather than on the basis of their disease types, such as breast or colorectal cancers.

An ambitious clinical trial set to start in July will match patients to treatments based on molecular abnormalities, rather than cancer types, testing 20 targeted drugs at once.